-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KInGtsPq/Gguy23XrH6ILDy0PM6fv7RMar73DPZ9bD8P0ozMfC7hQuEjCjXHzGgl TbnMd+ftI3kDlo+M9NMPFA== 0001193125-08-030836.txt : 20080214 0001193125-08-030836.hdr.sgml : 20080214 20080214122516 ACCESSION NUMBER: 0001193125-08-030836 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080214 DATE AS OF CHANGE: 20080214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Targanta Therapeutics Corp. CENTRAL INDEX KEY: 0001398161 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203971077 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-83189 FILM NUMBER: 08611278 BUSINESS ADDRESS: STREET 1: 222 THIRD AVENUE STREET 2: SUITE 2300 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 557-9020 MAIL ADDRESS: STREET 1: 222 THIRD AVENUE STREET 2: SUITE 2300 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BROOKSIDE CAPITAL PARTNERS FUND LP CENTRAL INDEX KEY: 0001028348 IRS NUMBER: 043313066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 111 HUNTINGTON AVENUE STREET 2: 617-516-2000 CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: 617-516-2000 MAIL ADDRESS: STREET 1: 111 HUNTINGTON AVENUE CITY: BOSTON STATE: MA ZIP: 02199 SC 13G 1 dsc13g.htm SCHEDULE 13G Schedule 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

(Rule 13d-102)

 

Information Statement Pursuant to Rules 13d-1 and 13d-2

Under the Securities Exchange Act of 1934

(Amendment No.     )*

 

 

 

 

Targanta Therapeutics Corporation

(Name of Issuer)

 

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

 

87612C100

(CUSIP Number)

 

 

December 31, 2007

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

 

 

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 87612C100   13G   Page 2 of 6 Pages

 

  1.  

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

            Brookside Capital Partners Fund, L.P.

            EIN No.: 04-3313066

    
  2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)  ¨

(b)  ¨

    
  3.  

SEC USE ONLY

 

    
  4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

            Delaware

    

 

NUMBER OF  

SHARES  

BENEFICIALLY  

OWNED BY  

EACH  

REPORTING  

PERSON  

WITH  

 

  

  5.    SOLE VOTING POWER

 

            2,771,682 shares

 

  6.    SHARED VOTING POWER

 

            0 shares

 

  7.    SOLE DISPOSITIVE POWER

 

            2,771,682 shares

 

  8.    SHARED DISPOSITIVE POWER

 

            0 shares

  9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

            2,771,682 shares

    
10.  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

   ¨
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

            13.15%

    
12.  

TYPE OF REPORTING PERSON

 

            PN

    

 

* Percentage is calculated using as the numerator, the total number of shares of Common Stock held by the Reporting Person (which includes a warrant to purchase 103,695 shares of Common Stock), and as the denominator, 20,969,257 shares of Common Stock outstanding, plus the 103,695 shares of Common Stock held by the Reporting Person in the form of a warrant.

 

Page 2 of 6 Pages

Item 1  

(a).

    Name of Issuer      
     The name of the issuer to which this filing on Schedule 13G relates is Targanta Therapeutics Corporation (the “Company”).      
Item 1  

(b).

    Address of Issuer’s Principal Executive Offices      
     The principal executive offices of the Company are located at 222 Third Street, Suite 2300, Cambridge, Massachusetts 02142.      
Item 2  

(a).

    Name of Person Filing      
     This Statement is being filed on behalf of Brookside Capital Partners Fund, L.P., a Delaware limited partnership (the “Brookside Fund”). Brookside Capital Investors, L.P., a Delaware limited partnership (“Brookside Investors”) is the sole general partner of the Brookside Fund. Brookside Capital Management, LLC, a Delaware limited liability company (“Brookside Management”), is the sole general partner of Brookside Investors. Mr. Domenic J. Ferrante is the sole managing member of Brookside Management.      
Item 2  

(b).

    Address of Principal Business Office or, if none, Residence      
     The principal business address of each of the Brookside Fund, Brookside Investors, Brookside Management and Mr. Ferrante is 111 Huntington Avenue, Boston, Massachusetts 02199.      
Item 2  

(c).

    Citizenship      
     Each of the Brookside Fund, Brookside Investors and Brookside Management is organized under the laws of the State of Delaware. Mr. Ferrante is a citizen of the United States.      
Item 2  

(d).

    Title of Class of Securities      
     The class of equity securities of the Company to which this filing on Schedule 13G relates is Common Stock, par value $0.0001 (“Common Stock”).      
Item 2  

(e).

    CUSIP Number      
     The CUSIP number of the Company’s Common Stock is 87612C100.      
Item 3.   If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.      
  (a)    ¨    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
  (b)    ¨    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).
  (c)    ¨    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
  (d)    ¨    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 

Page 3 of 6 Pages

  (e)    ¨    An investment adviser in accordance with §13d-1(b)(1)(ii)(E).
  (f)    ¨    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
  (g)    ¨    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
  (h)    ¨    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
  (i)    ¨    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
  (j)    ¨    Group, in accordance with §240.13d-1(b)(1)(ii)(J).
     ¨    If this statement is filed pursuant to §240.13d-1(c), check this box.

 

Item 4.    Ownership      
Item 4    (a).    Amount beneficially owned      
     

As of the close of business on December 31, 2007, the Brookside Fund owned 2,771,682 shares of Common Stock of the Company (including a warrant to purchase 103,695 shares of Common Stock of the Company). The Brookside Fund acts by and through its general partner, Brookside Investors. Brookside Investors acts by and through its general partner, Brookside Management. Mr. Domenic J. Ferrante is the managing member of Brookside Management and thus is the controlling person of Brookside Management. No person other than the respective owner referred to herein of the Common Stock is known to have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of such Common Stock.

 

As of December 31, 2007, Jay Venkatesan, a member of the Board of Directors of the Company, ceased to be an employee of Brookside Capital, LLC, an affiliate of the Brookside Fund. Consequently, the Brookside Fund qualified as a passive investor and has chosen to report its holdings of the Company as of December 31, 2007 on a Schedule 13G. The Brookside Fund is filing this 13G in accordance with its obligations under Rule 13d-1(d), but no change in the Brookside Fund’s beneficial ownership has occurred since it filed its Schedule 13D/A on November 2, 2007.

      
Item 4    (b).    Percent of Class      
      As of the close of business on December 31, 2007, the Brookside Fund was the beneficial owner of 13.15% of the Common Stock of the Company. The aggregate percentage of Common Stock reported owned by the Brookside Fund is based upon 20,969,257 shares of Common Stock outstanding, which is the total number of shares of Common Stock outstanding as of November 15, 2007, based on representations made in the Company’s Form 10-Q filed November 15, 2007 with the Securities and Exchange Commission.      
Item 4    (c).    Number of shares as to which such person has:      
      (i)    sole power to vote or to direct the vote:      
         2,771,682 shares      
      (ii)    shared power to vote or to direct the vote:      
         0 shares      
      (iii)    sole power to dispose or to direct the disposition of:      
         2,771,682 shares      
      (iv)    shared power to dispose or to direct the disposition of:      
         0 shares      
Item 5.    Ownership of Five Percent or Less of a Class   
   Not Applicable.   

 

Page 4 of 6 Pages

Item 6.    Ownership of More than Five Percent on Behalf of Another Person      
   Not Applicable.      
Item 7.    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:
   Not Applicable.
Item 8.    Identification and Classification of Members of the Group      
   Not Applicable.      
Item 9.    Notice of Dissolution of Group      
   Not Applicable.      

 

Page 5 of 6 Pages

Item 10.    Certification      
   By signing below, the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.      

Dated: February 14, 2008

 

BROOKSIDE CAPITAL PARTNERS FUND, L.P.
By:  

/s/ Domenic J. Ferrante

Name:   Domenic J. Ferrante
Title:   Managing Director
 -----END PRIVACY-ENHANCED MESSAGE-----